Abstract
In order to assess the effectiveness of sequential TI for the treatment of LD SCLC, we analyzed 69 patients who had received CAV-PVP chemotherapy consisting of cyclophosphamide, adriamycin, vincristine, cisplatin and etoposide, plus sequential TI between 1986 and 1992. TI was delivered at a total dose of 50 Gy, 5 fractions/week for 5 weeks, once patients achieved a maximal response to chemotherapy. Responding patients also received PCI at a total dose of 30 Gy, 5 fractions/week for 3 weeks. Thirty patients achieved CR by chemotherapy and an additional 10 achieved CR after TI, resulting in a CR rate of 58.0%. Of 40 patients achieving CR, 24 have relapsed so far; the primary (in 15) and the brain (in 4) were the major sites of relapse despite TI and PCI. The median survival time was 18.4 months, with a 2-year survival rate of 39% and 3-year survival rate of 20%. Almost all the patients encountered grade 3 or grade 4 leukopenia while receiving chemotherapy, but the toxicity of TI was generaly mild. This treatment is useful for patients with LD SCLC.
| Original language | English |
|---|---|
| Pages (from-to) | 218-224 |
| Number of pages | 7 |
| Journal | Japanese Journal of Thoracic Diseases |
| Volume | 31 |
| Issue number | SUPPL. |
| Publication status | Published - 1993 |
Fingerprint
Keywords
- chemo-radiotherapy
- sequential therapy
- small cell lung cancer
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
Cite this
CAV-PVP chemotherapy and sequential thoracic irradiation (TI) for patients with limited (LD) small cell lung cancer (SCLC). / Ueoka, H.; Ohnoshi, T.; Hiraki, S.; Kamei, H.; Tabata, Masahiro; Shibayama, T.; Miyatake, K.; Gemba, K.; Hiyama, J.; Kimura, J.
In: Japanese Journal of Thoracic Diseases, Vol. 31, No. SUPPL., 1993, p. 218-224.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - CAV-PVP chemotherapy and sequential thoracic irradiation (TI) for patients with limited (LD) small cell lung cancer (SCLC)
AU - Ueoka, H.
AU - Ohnoshi, T.
AU - Hiraki, S.
AU - Kamei, H.
AU - Tabata, Masahiro
AU - Shibayama, T.
AU - Miyatake, K.
AU - Gemba, K.
AU - Hiyama, J.
AU - Kimura, J.
PY - 1993
Y1 - 1993
N2 - In order to assess the effectiveness of sequential TI for the treatment of LD SCLC, we analyzed 69 patients who had received CAV-PVP chemotherapy consisting of cyclophosphamide, adriamycin, vincristine, cisplatin and etoposide, plus sequential TI between 1986 and 1992. TI was delivered at a total dose of 50 Gy, 5 fractions/week for 5 weeks, once patients achieved a maximal response to chemotherapy. Responding patients also received PCI at a total dose of 30 Gy, 5 fractions/week for 3 weeks. Thirty patients achieved CR by chemotherapy and an additional 10 achieved CR after TI, resulting in a CR rate of 58.0%. Of 40 patients achieving CR, 24 have relapsed so far; the primary (in 15) and the brain (in 4) were the major sites of relapse despite TI and PCI. The median survival time was 18.4 months, with a 2-year survival rate of 39% and 3-year survival rate of 20%. Almost all the patients encountered grade 3 or grade 4 leukopenia while receiving chemotherapy, but the toxicity of TI was generaly mild. This treatment is useful for patients with LD SCLC.
AB - In order to assess the effectiveness of sequential TI for the treatment of LD SCLC, we analyzed 69 patients who had received CAV-PVP chemotherapy consisting of cyclophosphamide, adriamycin, vincristine, cisplatin and etoposide, plus sequential TI between 1986 and 1992. TI was delivered at a total dose of 50 Gy, 5 fractions/week for 5 weeks, once patients achieved a maximal response to chemotherapy. Responding patients also received PCI at a total dose of 30 Gy, 5 fractions/week for 3 weeks. Thirty patients achieved CR by chemotherapy and an additional 10 achieved CR after TI, resulting in a CR rate of 58.0%. Of 40 patients achieving CR, 24 have relapsed so far; the primary (in 15) and the brain (in 4) were the major sites of relapse despite TI and PCI. The median survival time was 18.4 months, with a 2-year survival rate of 39% and 3-year survival rate of 20%. Almost all the patients encountered grade 3 or grade 4 leukopenia while receiving chemotherapy, but the toxicity of TI was generaly mild. This treatment is useful for patients with LD SCLC.
KW - chemo-radiotherapy
KW - sequential therapy
KW - small cell lung cancer
UR - http://www.scopus.com/inward/record.url?scp=0027849721&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027849721&partnerID=8YFLogxK
M3 - Article
C2 - 8007469
AN - SCOPUS:0027849721
VL - 31
SP - 218
EP - 224
JO - Respiratory Investigation
JF - Respiratory Investigation
SN - 2212-5345
IS - SUPPL.
ER -